Otonomy, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: San Diego CA United States (2008)

Organization Overview

First Clinical Trial
2010
NCT01084525
First Marketed Drug
2015
ciprofloxacin (cipro)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Otonomy, Inc. | OTONOMY INC

Active Ingredients

Marketed Drugs (1)

ciprofloxacin (cipro) (2015)

Drugs in Phase 3 Trials (3)

ciprofloxacin (cipro) (9 trials)

dexamethasone (1 trial)

urea (9 trials)

Drugs in Phase 2 Trials (2)

brain-derived neurotrophic factor (1 trial)

gacyclidine (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Deafness (Phase 2)

Hearing Loss (Phase 2)

Hearing Loss, Sensorineural (Phase 2)

Meniere Disease (Phase 3)

Otitis (Phase 3)

Otitis Externa (Phase 3)

Otitis Media (Phase 3)

Otitis Media with Effusion (Phase 3)

Tinnitus (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 5